236 related articles for article (PubMed ID: 34329660)
1. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
Carpino G; Cardinale V; Di Giamberardino A; Overi D; Donsante S; Colasanti T; Amato G; Mennini G; Franchitto M; Conti F; Rossi M; Riminucci M; Gaudio E; Alvaro D; Mancone C
J Hepatol; 2021 Dec; 75(6):1377-1386. PubMed ID: 34329660
[TBL] [Abstract][Full Text] [Related]
2. THBS1 and THBS2 Enhance the In Vitro Proliferation, Adhesion, Migration and Invasion of Intrahepatic Cholangiocarcinoma Cells.
Corbella E; Fara C; Covarelli F; Porreca V; Palmisano B; Mignogna G; Corsi A; Riminucci M; Maras B; Mancone C
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339060
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
[TBL] [Abstract][Full Text] [Related]
4. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
[TBL] [Abstract][Full Text] [Related]
6. MiR-19a enhances cell proliferation, migration, and invasiveness through enhancing lymphangiogenesis by targeting thrombospondin-1 in colorectal cancer.
Yin Q; Wang PP; Peng R; Zhou H
Biochem Cell Biol; 2019 Dec; 97(6):731-739. PubMed ID: 31199884
[TBL] [Abstract][Full Text] [Related]
7. Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis.
Sha M; Jeong S; Chen XS; Tong Y; Cao J; Sun HY; Xia L; Xu N; Wang X; Han LZ; Xi ZF; Zhang JJ; Kong XN; Xia Q
Int J Biol Sci; 2018; 14(10):1333-1342. PubMed ID: 30123080
[No Abstract] [Full Text] [Related]
8. Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
Peng M; Li H; Cao H; Huang Y; Yu W; Shen C; Gu J
J Gastroenterol; 2023 Sep; 58(9):908-924. PubMed ID: 37433897
[TBL] [Abstract][Full Text] [Related]
9. PEDF inhibits lymphatic metastasis of nasopharyngeal carcinoma as a new lymphangiogenesis inhibitor.
Luo C; Yin H; Gao T; Ma C; Liu J; Zhang T; Xu Z; Wang X; Zhang D; Qi W; Yang Z; Gao G; Yang X; Zhou T
Cell Death Dis; 2021 Mar; 12(4):295. PubMed ID: 33731707
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
11. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
12. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
13. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
14. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
Sirica AE; Strazzabosco M; Cadamuro M
Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
[TBL] [Abstract][Full Text] [Related]
15. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
[TBL] [Abstract][Full Text] [Related]
16. Regulating the angiogenic balance in tissues.
Pollina EA; Legesse-Miller A; Haley EM; Goodpaster T; Randolph-Habecker J; Coller HA
Cell Cycle; 2008 Jul; 7(13):2056-70. PubMed ID: 18642446
[TBL] [Abstract][Full Text] [Related]
17. Matricellular proteins in intrahepatic cholangiocarcinoma.
Sirica AE
Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
[TBL] [Abstract][Full Text] [Related]
18. Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1.
Huang WT; Chong IW; Chen HL; Li CY; Hsieh CC; Kuo HF; Chang CY; Chen YH; Liu YP; Lu CY; Liu YR; Liu PL
Cancer Lett; 2019 Feb; 442():287-298. PubMed ID: 30439539
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
Harris AR; Perez MJ; Munson JM
BMC Cancer; 2018 Jul; 18(1):718. PubMed ID: 29976154
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
